Global pharmaceutical company Eli Lilly (NYSE:LLY) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with ...

With a market cap of around $730 billion, Eli Lilly (NYSE: LLY) is one of the largest pharmaceutical companies on planet ...

Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin ...

Eli Lilly and Company (NYSE:LLY) is one of the best long term low volatility stocks to buy right now. On October 17, J.P.

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.1% in the morning session after the ...

October 30th is the day when Eli Lilly will report its third-quarter results, including sales of its 'superstars' Zepbound ...

or he could be attempting to push the company into accepting the price by creating public demand for it. Following the statement, both Novo Nordisk and Eli Lilly saw their stock prices dip. While the ...

Pharmaceutical titan Eli Lilly has delivered a quarterly report that dramatically surpassed market forecasts, sending waves ...

Offers a broad portfolio of pharmaceuticals targeting diabetes, oncology, immunology, neuroscience, and other therapeutic areas; key products include Zepbound ...

Eli Lilly holds the lead position in the weight management market right now. But Viking Therapeutics is working on a ...

Doctors called it “huge for patients,” if true. Patients who’ve struggled to afford the pricey medicines shared hope the price could be reached. Stocks of Novo Nordisk and Eli Lilly fell significantly ...

Eli Lilly shares rise as Q3 revenue jumps 54% to $17.6 billion, earnings top estimates, and analysts lift price targets on ...